Abvc biopharma executes a definitive agreement to receive license fees of $3m and royalties of 2% on future revenues

Fremont, ca, feb. 15, 2024 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neurology, and ophthalmology, announced today that it signed a definitive agreement to license certain of its healthcare-related expertise ("know-how") to senior paradise, inc. ("spi"), who will also lease certain of the company's properties (the "land") for further development related to the healthcare industry. the lease, spi may build a long-term care center for the elderly, plant factories, and good agricultural practices (gap) for botanical drug products and dietary supplements.
ABVC Ratings Summary
ABVC Quant Ranking